Harmony Biosciences RECONNECT Trial Reaches Enrollment Goal!

Anna De Sonia
Anna De Sonia

01 min read

The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.

A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:

About the Author

Anna De Sonia

Anna joined the NFXF team in 2024. She has many years of research experience, starting out as a clinical research coordinator at Rush University Medical Center in Chicago, IL back in 2010. There she worked on a variety of clinical trials in the pediatric neurology division, specializing in Fragile X research.